Table 1.
One-way analysis of variance (ANOVA) with Tukey–Kramer multiple comparisons test at time point 11.5 h
| Mean comparison | Difference (μm) | q | P value |
|---|---|---|---|
| Control vs. bradykinin | −56.515 | 5.044 | **P < 0.01 |
| Control vs. bradykinin + Hoe-140 | 2.625 | 0.2289 | n.s. P > 0.05 |
| Control vs. Hoe-140 | 27.302 | 1.897 | n.s. P > 0.05 |
| Control vs. bradykinin + blebbistatin | 86.910 | 5.201 | **P < 0.01 |
| Control vs. blebbistatin | 58.710 | 3.513 | n.s. P > 0.05 |
| Bradykinin vs. bradykinin + Hoe-140 | 59.140 | 5.157 | **P < 0.01 |
| Bradykinin vs. Hoe-140 | 83.817 | 5.824 | ***P < 0.001 |
| Bradykinin vs. bradykinin + blebbistatin | 143. 42 | 8.582 | ***P < 0.001 |
| Bradykinin vs. blebbistatin | 115.22 | 6.895 | ***P < 0.001 |
| Bradykinin + Hoe-140 vs. Hoe | 24.677 | 1.691 | n.s. P > 0.05 |
| Bradykinin + Hoe-140 vs. Bradykinin + blebbistatin | 84.285 | 4.990 | **P < 0.01 |
| Bradykinin + Hoe-140 vs. blebbistatin | 56.085 | 3.321 | n.s. P > 0.05 |
| Hoe vs. bradykinin + blebbistatin | 59.607 | 3.138 | n.s. P > 0.05 |
| Hoe vs. blebbistatin | 31.408 | 1.653 | n.s. P > 0.05 |
| Bradykinin + blebbistatin vs. blebbistatin | −28.200 | 1.355 | n.s. P > 0.05 |
n.s., not significant. P < 0.0001 (***) is considered extremely significant. If the value of q is greater than 4.071 then the P value is less than 0.05.